For various
pituitary adenomas, it has been demonstrated that
somatostatin receptor can be present. Pilot studies have shown that radio-
indium labeled
pentetreotide allows very good scintigraphic localization of
somatostatin receptor-bearing cell masses. Recently, the presence of CgA in
pituitary adenomas has also been demonstrated. MAb A11, raised against CgA, has been successfully used with a three-step ISG for the diagnosis of
neuroendocrine tumors. Therefore the combined use of three-step ISG with MAb A11 and radiolabeled
somatostatin can be useful in the diagnosis of
pituitary adenomas. Twelve patients, 5 secreting (group A) and 7 nonsecreting (group B)
pituitary adenomas, were enrolled in the study. All patients underwent three-step ISG, and, 2 wk later, scintigraphy with 111In-labeled
pentetreotide (
Octreoscan). Three-step ISG consisted of i.v. injection of 1 mg of biotinylated MAb A11 (first step), followed by 10 mg of
avidin (second step) and [99mTc]PnAO-
biotin (third step). Tomographic imaging were acquired for three-step ISG and
Octreoscan at 2 and 4 h after radiotracer injection, respectively. The results are the following: 2 patients of group A (secreting
tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive
pentetreotide study; all the patients of group B (nonsecreting
tumors) had a positive three-step ISG and 4 had a positive
pentetreotide scintigraphy. These data suggest the utility of the combined use of these techniques for a better diagnosis of
pituitary adenomas.